Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) closed at $97.61 up 1.17% from its previous closing price of $96.48. In other words, the price has increased by $1.17 from its previous closing price. On the day, 0.52 million shares were traded. RYTM stock price reached its highest trading level at $97.795 during the session, while it also had its lowest trading level at $95.8.
Ratios:
For a deeper understanding of Rhythm Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.64 and its Current Ratio is at 2.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $97.
On July 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $88.
BofA Securities Upgraded its Neutral to Buy on April 07, 2025, while the target price for the stock was maintained at $63.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 12 ’25 when Smith Hunter C sold 24,611 shares for $96.33 per share. The transaction valued at 2,370,832 led to the insider holds 116,915 shares of the business.
Smith Hunter C sold 3,477 shares of RYTM for $333,792 on Aug 13 ’25. The Chief Financial Officer now owns 116,915 shares after completing the transaction at $96.00 per share. On Aug 12 ’25, another insider, German Christopher Paul, who serves as the Corporate Controller & CAO of the company, sold 1,500 shares for $95.00 each. As a result, the insider received 142,500 and left with 922 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 6483266048 and an Enterprise Value of 6451708928. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.48. Its current Enterprise Value per Revenue stands at 41.281 whereas that against EBITDA is -36.676.
Stock Price History:
The Beta on a monthly basis for RYTM is 2.23, which has changed by 1.0723991 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $99.04, while it has fallen to a 52-week low of $43.57. The 50-Day Moving Average of the stock is 24.18%, while the 200-Day Moving Average is calculated to be 55.37%.
Shares Statistics:
For the past three months, RYTM has traded an average of 706.54K shares per day and 632020 over the past ten days. A total of 63.91M shares are outstanding, with a floating share count of 60.60M. Insiders hold about 8.54% of the company’s shares, while institutions hold 94.98% stake in the company. Shares short for RYTM as of 1753920000 were 4514524 with a Short Ratio of 6.39, compared to 1751241600 on 4853861. Therefore, it implies a Short% of Shares Outstanding of 4514524 and a Short% of Float of 8.74.
